st1481

Small moleculeexperimental

Clinical trial activity

8 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2002 (NCT00033202)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2/C=N/OC(C)(C)C
Mol. weight
447.49 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 7-t-butoxyiminomethylcamptothecin
  • 7-t-butoxyiminomethyl-camptothecin
  • gimatecan
  • gimatecan
  • gimatecan
  • gimatecan
  • lbq707
  • st1481
  • st 1481

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00493571Phase 1Aug 1, 2007Novartis, University of Texas at Houston
NCT00487058Phase 1May 1, 2007Novartis
NCT00441610Phase 1Jan 1, 2007Novartis
NCT00410358Phase 1Jun 1, 2006Novartis
NCT00420485Phase 1Mar 1, 2006Novartis
NCT00087061Phase 1/Phase 2 (Phase 2)May 1, 2004National Cancer Institute (NCI), University of California, Los Angeles
NCT00032903Phase 1/Phase 2 (Phase 2)Mar 1, 2002Leadiant Biosciences, Inc., Rhode Island Hospital
NCT00033202Phase 1Mar 1, 2002Harvard University, Leadiant Biosciences, Inc., Rhode Island Hospital
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit5412006
Leadiant Biosciences, Inc.For profit2222002
Rhode Island HospitalAcademic/Hospital2022002
Harvard UniversityAcademic/Hospital1012002
National Cancer Institute (NCI)Government1012004
University of California, Los AngelesAcademic/Hospital1112004
University of Texas at HoustonAcademic/Hospital1112007
7 organizations
Page 1 / 1